First Time in Human Study (FTIH) With Positron Emission Tomography (PET)
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study described in the present protocol consists of two sections. Part A is the first
administration into man to evaluate the safety, tolerability and pharmacokinetics of single
ascending doses of GSK1144814. The study is a single-blind, randomised, placebo-controlled
design in healthy male and female (of non-childbearing potential) subjects. Part B will be an
open-label design in healthy male subjects to assess the GSK1144814 neurokinin-1 (NK1)
receptor occupancy by positron emission tomography (PET) scanning with [11C]-GR205171